Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vertical HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B

NCT01743079

Chronic Hepatitis B Late Pregnancy Transmission +1 more

COMPLETED PHASE4

Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus

NCT01788371

Hepatitis B Infection Chronic Infection Viremia

COMPLETED PHASE4

"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission"

NCT07054359

HBV Infection Pregnancy

NOT_YET_RECRUITING NA

Tenofovir in Pregnancy to Prevent Mother to Child Transmission of Hepatitis B.

NCT04114890

Hepatitis B Tenofovir Pregnancy

COMPLETED PHASE2

The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children

NCT02301650

the Safety of Anti-viral Drugs Used in Late Pregnancy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mother-to-Child HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women, both in developed and in developing countries. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir; they can be used as a combo, as tenofovir+emtricitabine for instance. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission in this context, justifying this retrospective study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vertical Disease Transmission HBV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

children born from HIV-HBV women

Studying retrospectively their status for HBs Ag and HBc Ab

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* children born in the Maternity Department from HIV-HBV co-infected women
* whose mother was given a treatment with dual activity (HIV and HBV) during pregnancy